Novartis and Genmab's Arzerra has been approved in the US a new chronic lymphocytic leukaemia indication. The new FDA approval allows the drug to be used with a new combination of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback